Evercore ISI raised the firm’s price target on Zymeworks (ZYME) to $48 from $33 and keeps an Outperform rating on the shares. The $250M debt deal with Royalty Pharma (RPRX) is “a smart move,” providing significant optionality and the terms are “favorable,” allowing Zymeworks to retain upside while strengthening its balance sheet, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Earnings Call: Zanidatumab Drives Bullish Outlook
- Zymeworks price target raised to $46 from $32 at H.C. Wainwright
- Zymeworks: Strengthened Liquidity and Preserved Zanidatamab Royalty Upside Support Overweight Rating
- Zymeworks price target raised to $47 from $40 at Stifel
- Zymeworks’ Growth Clouded by High Clinical Failure Risk and Regulatory Uncertainty